Breast Neoplasms
Conditions
Keywords
Breast Neoplasms, cell-in-cell structures, Neoadjuvant therapy
Brief summary
Breast cancer is the most common malignant tumor in women worldwide and neoadjuvant therapy has been the standard care for local advanced breast cancer. Moreover, neoadjuvant therapy undoubtedly provides an ideal model to evaluate the response to therapy. Cell-in-cell structures (CICs) refer to the presence of one or more cells inside host cell, which generally leads to the death of inner cells. Notably, established evidences indicated that CICs were present in breast cancer and tend to impact patient survival. However, whether CICs profile could predict efficacy of therapy remains unclear. In this prospective cohort study, the CICs number and profile will be detected in tumor tissue before and after the neoadjuvant therapy. Then the association between CICs number including dynamic changing and response rate will be explored.
Interventions
DRUGNeoadjuvant therapy
all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
Sponsors
Beijing Shijitan Hospital, Capital Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65, female; * Pathological biopsy confirmed invasive ductal carcinoma; * Karnofsky Performance Status (KPS)≥ 60, expected survival ≥4 months; * Locally advanced breast cancer (HER2-positive disease and TNBC, ≥cT1c or ≥cN0； HER2-negative，HR positive disease，≥cT2 or ≥cN1；Large primary tumor relative to breast size in a patient who desires breast conservation) ; * According to the RECIST1.1 standard, at least one measurable lesion exists;
Exclusion criteria
* Pregnant or lactating women; * Left ventricular ejection fraction less than 50%; * History of malignant tumor and concurrent occurrence of other tumors; * Serious medical pathology, such as congestive heart failure; unstable angina; uncontrolled high risk arrhythmias, and other serious illness or medical condition that may interfere with the study; * Refuse to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR(complete pathological response) | Up to 24 weeks. | no invasive malignant cells identifiable in sections from the site of the tumor（Miller-Payne grades 5） the Miller-Payne grades 4 and 5 patients are grouped as responders. |
| Objective response rate (ORR) | Up to 24 weeks. | Response Evaluation Criteria in Solid Tumors (RECIST)：Progressive Disease (PD); Partial Response (PR); Complete Response (CR); Stable Disease (SD) Objective response rate (ORR), defined as the proportion of patients with a complete response (CR) partial response (PR) to treatment. |
| Quantification of CIC structure in tumor tissue | Up to 24 weeks. | CICs number and subtypes in tumor tissue (Core needle biopsy specimens before and after neoadjuvant therapy and surgical specimens based on neoadjuvant therapy.) |
Other
| Measure | Time frame | Description |
|---|---|---|
| CA125(Carbohydrate antigen125) | Up to 24 weeks. | Counts of international units per milliliter (IU/mL) of tumor marker CA 125 |
| Disease-free survival (DFS) | Within 5 years after surgery | It refers to the length of time from the start of medication after enrollment to the death of the patient because of the recurrence, distant metastasis of the disease, invasive contralateral breast cancer, or any other cause. |
| CA199(Carbohydrate antigen199) | Up to 24 weeks. | Counts of international units per milliliter (IU/mL) of tumor marker CA 199 |
| Overall survival (OS) | Within 10 years after surgery | It refers to the length of time from the start of treatment to the death of the patient. |
| CEA(carcinoembryonic antigen) | Up to 24 weeks. | Counts of international units per milliliter (IU/mL) of tumor marker CEA |
Countries
China
Contacts
Primary ContactHongyan Huang, PHD
Outcome results
None listed